PetLife Pharmaceuticals, Inc. (a US Veterinary Pharmaceutical company) has developed a high potency veterinary cancer medication for pets called VitalZul™ for which they have filed for patent protection in the United States and India.  The patent application is entitled “A Composition for Targeting Cancer in Canines and Humans”.  The patent formulation is intended for both animal and human use, pending further testing.

As the components of the formulation of VitalZul™ are natural as opposed to synthetic testing has shown them to have a very minimal level of toxicity.

Scientists and researchers will continue testing VitalZul™ with the aim of obtaining FDA approval and for the product to be on sale by the end of 2018.